Aptevo Therapeutics Inc (APVO)
2.40 x 1 2.49 x 4
Post-market by (Cboe BZX)
2.41 +0.03 (+1.26%) 03/14/25 [NASDAQ]
2.40 x 1 2.49 x 4
Post-market 2.47 +0.06 (+2.49%) 16:44 ET
for Fri, Mar 14th, 2025
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
Cash Flows From Operating Activities | |||||
Net Income | -24,130 | -17,411 | 8,027 | -28,457 | -17,750 |
Depreciation Amortization | 352 | 567 | 901 | 1,144 | 1,406 |
Accounts payable and accrued liabilities | -1,017 | 518 | -394 | -1,915 | -702 |
Other Working Capital | -1,076 | 2,911 | 2,144 | -2,655 | -2,406 |
Other Operating Activity | 2,086 | 1,685 | -31,700 | 10,204 | -9,866 |
Operating Cash Flow | $-23,785 | $-11,730 | $-21,022 | $-21,679 | $-29,318 |
Cash Flows From Investing Activities | |||||
PPE Investments | N/A | N/A | -29 | -713 | -88 |
Net Acquisitions | N/A | N/A | N/A | N/A | 28,120 |
Investing Cash Flow | $N/A | $N/A | $-29 | $-713 | $28,032 |
Cash Flows From Financing Activities | |||||
Debt Issued | N/A | N/A | N/A | N/A | 24,731 |
Debt Repayment | N/A | -3,467 | -12,267 | -10,550 | -22,104 |
Common Stock Issued | 15,599 | 9,475 | 6,934 | 11,438 | 21,258 |
Other Financing Activity | -4 | -10 | 2,717 | 25,273 | -11 |
Financing Cash Flow | $15,595 | $5,998 | $-2,616 | $26,161 | $23,874 |
Beginning Cash Position | 16,904 | 22,636 | 46,303 | 42,534 | 19,946 |
End Cash Position | 8,714 | 16,904 | 22,636 | 46,303 | 42,534 |
Net Cash Flow | $-8,190 | $-5,732 | $-23,667 | $3,769 | $22,588 |
Free Cash Flow | |||||
Operating Cash Flow | -23,785 | -11,730 | -21,022 | -21,679 | -29,318 |
Capital Expenditure | N/A | N/A | -29 | -713 | -88 |
Free Cash Flow | -23,785 | -11,730 | -21,051 | -22,392 | -29,406 |